Champions Oncology Q1 Revenue Rises 8.8% as Margin Expands

Earnings
โดย Zacks Investment Research·US·Read original
Summary · why it matters

Champions Oncology reported first-quarter fiscal 2027 revenues of $15.2 million, up 8.8% from $13.9 million a year earlier, while its GAAP net loss narrowed to $426,000 from $466,000 and adjusted earnings per share rose to 5 cents from 1 cent. Within the company's single reportable oncology-services segment, pharmacology services revenues rose 6.9% to $14.2 million from $13.2 million, Translational Oncology Solutions data-license revenues jumped 187.1% to $893,000 from $311,000, and other TOS revenues declined 59.7% to $183,000 from $454,000. Oncology services margin improved to 51% from 43%, cost of oncology revenues fell 5.8% to $7.5 million, and adjusted EBITDA rose to $671,000 from $59,000, even as total costs and operating expenses increased 7.7% to $15.6 million. The company used $492,000 of cash in operating activities against $600,000 generated a year earlier, ended July with $4.4 million in cash, and said cash on hand plus expected operating cash flows should fund operations through at least September 2027. CEO Robert Brainin credited improved study execution and conversion in the core research-services business, and management said it continues talks with venture groups and potential pharmaceutical partners on outside funding or a licensing partnership for Corellia without giving a timetable, while providing no formal revenue or earnings guidance.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Champions Oncology Inc
CSBR
▲ PositiveCapitalrelevance

Q1 revenue rose 8.8% to $15.2M, net loss narrowed, adjusted EPS rose to 5 cents, and adjusted EBITDA jumped to $671K from $59K.

Theme Impact 1

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·21hRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·23hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·1dRead more →
© 2026 MarketDXNews